LB0012 HEADLINE RESULTS FOR A PHASE 4, 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS ADVERSE EVENTS OF SPECIAL INTEREST (AESI) IN ADULTS WITH ACTIVE, AUTOANTIBODY-POSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) RECEIVING BELIMUMAB
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.8720
Abstract: Background Belimumab (BEL) is approved in adults with active, autoantibody-positive SLE. Phase 2, 3 and long-term extension studies showed a favourable benefit-risk profile. However, numerical differences in the incidence of mortality, infections, hypersensitivity reactions and… read more here.
Keywords: gsk employee; gsk; shareholder gsk; study ... See more keywords